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Abstract
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer
risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast
and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers.
We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.761028, HR = 1.14, 95%
CI: 1.09–1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.461028,
HR = 1.27, 95% CI: 1.17–1.38) and 4q32.3 (rs4691139, P = 3.461028, HR = 1.20, 95% CI: 1.17–1.38). The 4q32.3 locus was not
associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The
17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 261024). These loci may lead to an
improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of
the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1
carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk. Similarly, based on the known
ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing
ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may
have important implications for risk prediction and clinical management for BRCA1 carriers.
Citation: Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, et al. (2013) Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci
Associated with Breast and Ovarian Cancer Risk. PLoS Genet 9(3): e1003212. doi:10.1371/journal.pgen.1003212
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Introduction
Breast and ovarian cancer risk estimates for BRCA1 mutation
carriers vary by the degree of family history of the disease,
suggesting that other genetic factors modify cancer risks for this
population [1–4]. Studies by the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) have shown that a subset of
common alleles influencing breast and ovarian cancer risk in the
general population are also associated with cancer risk in BRCA1
mutation carriers [5–11]. In particular, the breast cancer
associations were limited to loci associated with estrogen receptor
(ER)-negative breast cancer in the general population (6q25.1,
12p11 and TOX3) [8–11].
To systematically search for loci associated with breast or
ovarian cancer risk for BRCA1 carriers we previously conducted a
two-stage genome-wide association study (GWAS) [12]. The initial
stage involved analysis of 555,616 SNPs in 2383 BRCA1 mutation
carriers (1,193 unaffected and 1,190 affected). After replication
testing of 89 SNPs showing the strongest association, with 5,986
BRCA1 mutation carriers, a locus on 19p13 was shown to be
associated with breast cancer risk for BRCA1 mutation carriers.
The same locus was also associated with the risk of estrogen-
receptor (ER) negative and triple negative (ER, Progesterone and
HER2 negative) breast cancer in the general population [12,13].
The Collaborative Oncological Gene-environment Study
(COGS) consortium recently developed a 211,155 SNP custom
genotyping array (iCOGS) in order to provide cost-effective
genotyping of common and rare genetic variants to identify novel
loci that explain the residual genetic variance of breast, ovarian
Novel Modifiers of BRCA1 Cancer Risk
PLOS Genetics | www.plosgenetics.org 5 March 2013 | Volume 9 | Issue 3 | e1003212
and prostate cancers and fine-map known susceptibility loci. A
total of 32,557 SNPs on the iCOGS array were selected on the
basis of the BRCA1 GWAS for the purpose of identifying breast
and ovarian cancer risk modifiers for BRCA1 mutation carriers.
Genotype data from the iCOGS array were obtained for 11,705
samples from BRCA1 carriers and the 17 most promising SNPs
were then genotyped in an additional 2,646 BRCA1 carriers. In
this manuscript we report on the novel risk modifier loci identified
by this multi-stage GWAS. No study has previously shown how the
absolute risks of breast and ovarian cancer for BRCA1 mutation
carriers vary by the combined effects of risk modifying loci. Here
we use the results from this study, in combination with previously
identified modifiers, to obtain absolute risks of developing breast
and ovarian cancer for BRCA1 mutation carriers based on the joint
distribution of all known genetic risk modifiers.
Materials and Methods
Ethics statement
All carriers participated in clinical or research studies at the host
institutions, approved by local ethics committees.
Study subjects
BRCA1 mutation carriers were recruited by 45 study centers in
25 countries through CIMBA. The majority were recruited
through cancer genetics clinics, and enrolled into national or
regional studies. The remainder were identified by population-
based sampling or community recruitment. Eligibility for CIMBA
association studies was restricted to female carriers of pathogenic
BRCA1 mutations age 18 years or older at recruitment.
Information collected included year of birth, mutation description,
self-reported ethnic ancestry, age at last follow-up, ages at breast or
ovarian cancer diagnoses, and age at bilateral prophylactic
mastectomy and oophorectomy. Information on tumour charac-
teristics, including ER-status of the breast cancers, was also
collected. Related individuals were identified through a unique
family identifier. Women were included in the analysis if they
carried mutations that were pathogenic according to generally
recognized criteria.
GWAS stage 1 samples. A total of 2,727 BRCA1 mutation
carriers were genotyped on the Illumina Infinium 610K array
(Figure 1). Of these 1,426 diagnosed with a first breast cancer
under age 40 were considered ‘‘affected’’ in the breast cancer
association analysis and 683 diagnosed with an ovarian cancer at
any time were considered as ‘‘affected’’ in the ovarian cancer
analysis. ‘‘Unaffected’’ in both analyses were over age 35 (Table
S1) [12].
Replication study samples. All eligible BRCA1 carriers
from CIMBA with sufficient DNA were genotyped, including
those used in Stage 1. In total, 13,310 samples from 45 centers in
25 countries were genotyped using the iCOGS array (Table S2).
Among the 13,310 samples, those that were genotyped in the
GWAS stage 1 SNP selection stage are referred to as ‘‘stage 1’’
samples, and the remainder are ‘‘stage 2’’ samples. An additional
2,646 BRCA1 samples ‘‘stage 3’’ were genotyped on an iPLEX
Mass Array of 17 SNPs from 12 loci selected after an interim
analysis of iCOGS array data and were available for analysis after
quality control (QC) (Figure 1). Carriers of pathogenic mutations
in BRCA2 were drawn from a parallel GWAS of genetic modifiers
for BRCA2 mutation carriers. BRCA2 mutation carriers were
recruited from CIMBA through 47 studies which were largely the
same as the studies that contributed to the BRCA1 GWAS with
similar eligibility criteria. Samples from BRCA2 mutation carriers
were also genotyped using the iCOGS array. Details of this
experiment are described elsewhere [14]. A total of 8,211 samples
were available for analysis after QC.
iCOGS SNP array
The iCOGS array was designed in a collaboration among the
Breast Cancer Association Consortium (BCAC), Ovarian Cancer
Association Consortium (OCAC), the Prostate Cancer Association
Group to Investigate Cancer Associated Alterations in the
Genome (PRACTICAL) and CIMBA. The general aims for
designing the iCOGS array were to replicate findings from GWAS
for identifying variants associated with breast, ovarian or prostate
cancer (including subtypes and SNPs potentially associated with
disease outcome), to facilitate fine-mapping of regions of interest,
and to genotype ‘‘candidate’’ SNPs of interest within the consortia,
including rarer variants. Each consortium was given a share of the
array: nominally 25% of the SNPs each for BCAC, PRACTICAL
and OCAC; 17.5% for CIMBA; and 7.5% for SNPs of common
interest between the consortia. The final design comprised
220,123 SNPs, of which 211,155 were successfully manufactured.
A total of 32,557 SNPs on the iCOGS array were selected based
on 8 separate analyses of stage 1 of the CIMBA BRCA1 GWAS
that included 2,727 BRCA1 mutation carriers [12]. After
imputation for all SNPs in HapMap Phase II (CEU) a total of
2,568,349 (imputation r2.0.30) were available for analysis.
Markers were evaluated for associations with: (1) breast cancer;
(2) ovarian cancer; (3) breast cancer restricted to Class 1 mutations
(loss-of-function mutations expected to result in a reduced
transcript or protein level due to nonsense-mediated RNA decay);
(4) breast cancer restricted to Class 2 mutations (mutations likely to
generate stable proteins with potential residual or dominant
negative function); (5) breast cancer by tumor ER-status; (6) breast
cancer restricted to BRCA1 185delAG mutation carriers; (7) breast
cancer restricted to BRCA1 5382insC mutation carriers; and (8)
breast cancer by contrasting the genotype distributions in BRCA1
mutation carriers, against the distribution in population-based
controls. Analyses (1) and (2) were based on both imputed and
observed genotypes, whereas the rest were based on only the
observed genotypes. SNPs were ranked according to the 1 d.f.
score-test for trend P-value (described below) and selected for
inclusion based on nominal proportions of 61.5%, 20%, 2.5%,
2.5%, 2.5%, 0.5%, 0.5% and 10.0% for analyses (1) to (8). SNP
duplications were not allowed and SNPs with a pairwise r2$0.90
with a higher-ranking SNP were only allowed (up to a maximum
Author Summary
BRCA1 mutation carriers have increased and variable risks
of breast and ovarian cancer. To identify modifiers of
breast and ovarian cancer risk in this population, a multi-
stage GWAS of 14,351 BRCA1 mutation carriers was
performed. Loci 1q32 and TCF7L2 at 10q25.3 were
associated with breast cancer risk, and two loci at 4q32.2
and 17q21.31 were associated with ovarian cancer risk. The
4q32.3 ovarian cancer locus was not associated with
ovarian cancer risk in the general population or in BRCA2
carriers and is the first indication of a BRCA1-specific risk
locus for either breast or ovarian cancer. Furthermore,
modeling the influence of these modifiers on cumulative
risk of breast and ovarian cancer in BRCA1 mutation
carriers for the first time showed that a wide range of
individual absolute risks of each cancer can be estimated.
These differences suggest that genetic risk modifiers may
be incorporated into the clinical management of BRCA1
mutation carriers.
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of 2) if the P-value for association was ,1024 for analyses (1) and
(2) and ,1025 for other analyses. SNPs with poor Illumina design
scores were replaced by the SNP with the highest r2 (among SNPs
with r2.0.80 based on HapMap data) that had a good quality
design score. The analysis of associations with breast and ovarian
cancer risks presented here included all 32,557 SNPs on iCOGS
that were selected on the basis of the BRCA1 GWAS.
Genotyping and quality control
iCOGS genotyping. Genotyping was performed at Mayo
Clinic. Genotypes for samples genotyped on the iCOGS array
were called using Illumina’s GenCall algorithm (Text S1). A total
of 13,510 samples were genotyped for 211,155 SNPs. The sample
and SNP QC process is summarised in Table S3. Of the 13,510
samples, 578 did not fulfil eligibility criteria based on phenotypic
Figure 1. Study design for selection of the SNPs and genotyping of BRCA1 samples. GWAS data from 2,727 BRCA1 mutation carriers were
analysed for associations with breast and ovarian cancer risk and 32,557 SNPs were selected for inclusion on the iCOGS array. A total of 11,705 BRCA1
samples (after quality control (QC) checks) were genotyped on the 31,812 BRCA1-GWAS SNPs from the iCOGS array that passed QC. Of these samples,
2,387 had been genotyped at the SNP selection stage and are referred to as ‘‘stage 1’’ samples, whereas 9,318 samples were unique to the iCOGS
study (‘‘Stage 2’’ samples). Next, 17 SNPs that exhibited the most significant associations with breast and ovarian cancer were selected for genotyping
in a third stage involving an additional 2,646 BRCA1 samples (after QC).
doi:10.1371/journal.pgen.1003212.g001
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data and were excluded. A step-wise QC process was applied to
the remaining samples and SNPs. Samples were excluded due to
inferred gender errors, low call rates (,95%), low or high
heterozygosity and sample duplications (cryptic and intended). Of
the 211,155 markers genotyped, 9,913 were excluded due to Y-
chromosome origin, low call rates (,95%), monomorphic SNPs,
or SNPs with Hardy-Weinberg equilibrium (HWE) P,1027 under
a country-stratified test statistic [15] (Table S3). SNPs that gave
discordant genotypes among known sample duplicates were also
excluded. Multi-dimensional scaling was used to exclude individ-
uals of non-European ancestry. We selected 37,149 weakly
correlated autosomal SNPs (pair-wise r2,0.10) to compute the
genomic kinship between all pairs of BRCA1 carriers, along with
197 HapMap samples (CHB, JPT, YRI and CEU). These were
converted to distances and subjected to multidimensional scaling
(Figure S1). Using the first two components, we calculated the
proportion of European ancestry for each individual [12] and
excluded samples with .22% non-European ancestry (Figure S1).
A total of 11,705 samples and 201,242 SNPs were available for
analysis, including 31,812 SNPs selected by the BRCA1 GWAS.
The genotyping cluster plots for all SNPs that demonstrated
genome-wide significance level of association or are presented
below, were checked manually for quality (Figure S2).
iPLEX analysis. The most significant SNPs from 4 loci
associated with ovarian cancer and 8 loci associated with breast
cancer were selected (17 SNPs in total) for stage 3 genotyping.
Genotyping using the iPLEX Mass Array platform was performed
at Mayo Clinic. CIMBA QC procedures were applied. Samples
that failed for $20% of the SNPs were excluded from the analysis.
No SNPs failed HWE (P,0.01). The concordance among
duplicates was $98%. Mutation carriers of self-reported non-
European ancestry were excluded. A total of 2,646 BRCA1 samples
were eligible for analysis after QC.
Statistical methods
The main analyses were focused on the evaluation of
associations between each genotype and breast cancer or ovarian
cancer risk separately. Analyses were carried out within a survival
analysis framework. In the breast cancer analysis, the phenotype of
each individual was defined by age at breast cancer diagnosis or
age at last follow-up. Individuals were followed until the age of the
first breast cancer diagnosis, ovarian cancer diagnosis, or bilateral
prophylactic mastectomy, whichever occurred first; or last
observation age. Mutation carriers censored at ovarian cancer
diagnosis were considered unaffected. For the ovarian cancer
analysis, the primary endpoint was the age at ovarian cancer
diagnosis. Mutation carriers were followed until the age of ovarian
cancer diagnosis, or risk-reducing salpingo-oophorectomy (RRSO)
or age at last observation. In order to maximize the number of
ovarian cancer cases, breast cancer was not considered as a
censoring event in this analysis, and mutation carriers who
developed ovarian cancer after a breast cancer diagnosis were
considered as affected in the ovarian cancer analysis.
Association analysis. The majority of mutation carriers
were sampled through families seen in genetic clinics. The first
tested individual in a family is usually someone diagnosed with
cancer at a relatively young age. Such study designs tend to lead to
an over-sampling of affected individuals, and standard analytical
methods like Cox regression may lead to biased estimates of the
risk ratios [16,17]. To adjust for this potential bias the data were
analyzed within a survival analysis framework, by modeling the
retrospective likelihood of the observed genotypes conditional on
the disease phenotypes. A detailed description of the retrospective
likelihood approach has been published [17,18]. The associations
between genotype and breast cancer risk at both stages were
assessed using the 1 d.f. score test statistic based on this
retrospective likelihood [17,18]. To allow for the non-indepen-
dence among related individuals, we accounted for the correlation
between the genotypes by estimating the kinship coefficient for
each pair of individuals using the available genomic data
[16,19,20] and by robust variance estimation based on reported
family membership [21]. We chose to present P-values based on
the kinship adjusted score test as it utilises the degree of
relationship between individuals. A genome-wide level of signif-
icance of 561028 was used [22]. These analyses were performed
in R using the GenABEL [23] libraries and custom-written
functions in FORTRAN and Python.
To estimate the magnitude of the associations (HRs), the effect
of each SNP was modeled either as a per-allele HR (multiplicative
model) or as genotype-specific HRs, and were estimated on the
log-scale by maximizing the retrospective likelihood. The retro-
spective likelihood was fitted using the pedigree-analysis software
MENDEL [17,24]. As sample sizes varied substantially between
contributing centers heterogeneity was examined at the country
level. All analyses were stratified by country of residence and used
calendar-year and cohort-specific breast cancer incidence rates for
BRCA1 [25]. Countries with small number of mutation carriers
were combined with neighbouring countries to ensure sufficiently
large numbers within each stratum (Table S2). USA and Canada
were further stratified by reported Ashkenazi Jewish (AJ) ancestry
due to large numbers of AJ carriers. In stage 3 analysis involving
several countries with small numbers of mutation carriers, we
assumed only 3 large strata (Europe, Australia, USA/Canada).
The combined iCOGS stage and stage 3 analysis was also
stratified by stage of the experiment. The analysis of associations
by breast cancer ER-status was carried out by an extension of the
retrospective likelihood approach to model the simultaneous effect
of each SNP on more than one tumor subtype [26] (Text S1).
Competing risk analysis. The associations with breast and
ovarian cancer risk simultaneously were assessed within a compet-
ing risk analysis framework [17] by estimating HRs simultaneously
for breast and ovarian cancer risk. This analysis provides unbiased
estimates of association with both diseases and more powerful tests
of association in cases where an association exists between a variant
and at least one of the diseases [17]. Each individual was assumed to
be at risk of developing either breast or ovarian cancer, and the
probabilities of developing each disease were assumed to be
independent conditional on the underlying genotype. A different
censoring process was used, whereby individuals were followed up
to the age of the first breast or ovarian cancer diagnosis and were
considered to have developed the corresponding disease. No follow-
up was considered after the first cancer diagnosis. Individuals
censored for breast cancer at the age of bilateral prophylactic
mastectomy and for ovarian cancer at the age of RRSO were
assumed to be unaffected for the corresponding disease. The
remaining individuals were censored at the last observation age and
were assumed to be unaffected for both diseases.
Imputation. For the SNP selection process, the MACH
software was used to impute non-genotyped SNPs based on the
phased haplotypes from HapMap Phase II (CEU, release 22). The
IMPUTE2 software [27] was used to impute non-genotyped SNPs
for samples genotyped on the iCOGS array (stage 1 and 2 only),
based on the 1,000 Genomes haplotypes (January 2012 version).
Associations between each marker and cancer risk were assessed
using a similar score test to that used for the observed SNPs, but
based on the posterior genotype probabilities at each imputed
marker for each individual. In all analyses, we considered only
SNPs with imputation information/accuracy r2.0.30.
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Absolute breast and ovarian cancer risks by combined
SNP profile. We estimated the absolute risk of developing
breast and ovarian cancer based on the joint distribution of all
SNPs that were significantly associated with risk for BRCA1
mutation carriers based on methods previously applied to BRCA2
carriers [28]. We assumed that the average, age-specific breast and
ovarian cancer incidences for BRCA1 mutation carriers, over all
modifying loci, agreed with published penetrance estimates for
BRCA1 [25]. The model assumed independence among the
modifying loci and we used only the SNP with the strongest
evidence of association from each region. We used only loci
identified through the BRCA1 GWAS that exhibited associations
at a genome-wide significance level, and loci that were identified
through population-based GWAS of breast or ovarian cancer risk,
but were also associated with those risks for BRCA1 mutation
carriers. For each SNP, we used the per-allele HR and minor allele
frequencies estimated from the present study. Genotype frequen-
cies were obtained under the assumption of HWE.
Results
Samples from 11,705 BRCA1 carriers from 45 centers in 25
countries yielded high-quality data for 201,242 SNPs on the
iCOGS array. The array included 31,812 BRCA1 GWAS SNPs,
which were analyzed here for their associations with breast and
ovarian cancer risk for BRCA1 mutation carriers (Table S2). Of the
11,705 BRCA1 mutation carriers, 2,387 samples had also been
genotyped for stage 1 of the GWAS and 9,318 were unique to the
stage 2 iCOGS study.
Breast cancer associations
When restricting analysis to stage 2 samples (4,681 unaffected,
4,637 affected), there was little evidence of inflation in the
association test-statistic (l= 1.038; Figure S3). Combined analysis
of stage 1 and 2 samples (5,784 unaffected, 5,920 affected) revealed
66 SNPs in 28 regions with P,1024 (Figure S4). These included
variants from three loci (19p13, 6q25.1, 12p11) previously
associated with breast cancer risk for BRCA1 mutation carriers
(Table 1). Further evaluation of 18 loci associated with breast
cancer susceptibility in the general population found that only the
TOX3, LSP1, 2q35 and RAD51L1 loci were significantly associated
with breast cancer for BRCA1 carriers (Table 1, Table S4).
After excluding SNPs from the known loci, there were 39 SNPs in
25 regions with P = 1.261026–1.061024. Twelve of these SNPs
were genotyped by iPLEX in an additional 2,646 BRCA1 carriers
(1,252 unaffected, 1,394 affected, ‘‘stage 3’’ samples, Table S5).
There was additional evidence of association with breast cancer risk
for four SNPs at two loci (P,0.01, Table 2). When all stages were
combined, SNPs rs2290854 and rs6682208 (r2 = 0.84) at 1q32, near
MDM4, had combined P-values of association with breast cancer
risk of 1.461027 and 461027,respectively. SNPs rs11196174 and
rs11196175 (r2 = 0.96) at 10q25.3 (in TCF7L2) had combined P-
values of 7.561027 and 1.261026. Analysis within a competing
risks framework, where associations with breast and ovarian cancer
risks are evaluated simultaneously [17], revealed stronger associa-
tions with breast cancer risk for all 4 SNPs, but no associations with
ovarian cancer (Table 3). In particular, we observed a genome-wide
significant association between the minor allele of rs2290854 from
1q32 and breast cancer risk (per-allele HR: 1.14; 95%CI: 1.09–
1.20; p = 2.761028). Country-specific HR estimates for all SNPs are
shown in Figure S5. Analyses stratified by BRCA1 mutation class
revealed no significant evidence of a difference in the associations of
any of the SNPs by the predicted functional consequences of BRCA1
mutations (Table S6). SNPs in the MDM4 and TCF7L2 loci were
associated with breast cancer risk for both class1 and class2
mutation carriers.
Both the 1q32 and 10q25.3 loci were primarily associated with
ER-negative breast cancer for BRCA1 (rs2290854: ER-negative
HR = 1.16, 95%CI: 1.10–1.22, P = 1.261027; rs11196174:
HR = 1.14, 95%CI: 1.07–1.20, P = 9.661026), although the differ-
ences between the ER-negative and ER-positive HRs were not
significant (Table S7). Given that ER-negative breast cancers in
BRCA1 and BRCA2 mutation carriers are phenotypically similar
[29], we also evaluated associations between these SNPs and ER-
negative breast cancer in 8,211 BRCA2 mutation carriers. While the
10q25.3 SNPs were not associated with overall or ER-negative breast
cancer risk for BRCA2 carriers, the 1q32 SNPs were associated with
ER-negative (rs2290854 HR = 1.16, 95%CI:1.01–1.34, P = 0.033;
rs6682208 HR = 1.19, 95%CI:1.04–1.35, P = 0.016), but not ER-
positive breast cancer (rs2290854 P-diff = 0.006; rs6682208 P-
diff = 0.001). Combining the BRCA1 and BRCA2 samples provided
strong evidence of association with ER-negative breast cancer
(rs2290854: P = 1.2561028; rs6682208: P = 2.561027).
The iCOGS array included additional SNPs from the 1q32
region that were not chosen based on the BRCA1 GWAS. Of these
non-BRCA1 GWAS SNPs, only SNP rs4951407 was more
significantly associated with risk than the BRCA1-GWAS selected
SNPs (P = 3.361026, HR = 1.12, 95%CI:1.07–1.18, using stage 1
and stage 2 samples). The evidence of association with breast cancer
risk was again stronger under the competing risks analysis
(HR = 1.14, 95%CI: 1.08–1.20, P = 6.161027). Backward multiple
regression analysis, considering only the genotyped SNPs (P,0.01),
revealed that the most parsimonious model included only
rs4951407. SNPs from the 1000 Genomes Project, were imputed
for the stage 1 and stage 2 samples (Figure S6). Only imputed SNP
rs12404974, located between PIK3C2B and MDM4 (r2 = 0.77 with
rs4951407), was more significantly associated with breast cancer
(P = 2.761026) than any of the genotyped SNPs. None of the
genotyped or imputed SNPs from 10q25.3 provided P-values
smaller than those for rs11196174 and rs11196175 (Figure S7).
Ovarian cancer associations
Analyses of associations with ovarian cancer risk using the stage 2
samples (8,054 unaffected, 1,264 affected) revealed no evidence of
inflation in the association test-statistic (l= 1.039, Figure S3). In the
combined analysis of stage 1 and 2 samples (9866 unaffected, 1839
affected), 62 SNPs in 17 regions were associated with ovarian cancer
risk for BRCA1 carriers at P,1024 (Figure S3). These included
SNPs in the 9p22 and 3q25 loci previously associated with ovarian
cancer risk in both the general population and BRCA1 carriers [6,7]
(Table 1). Associations (P,0.01) with ovarian cancer risk were also
observed for SNPs in three other known ovarian cancer suscepti-
bility loci (8q24, 17q21, 19p13), but not 2q31 (Table 1). For all loci
except 9p22, SNPs were identified that displayed smaller P-values of
association than previously published results [5–7].
After excluding SNPs from known ovarian cancer susceptibility
regions, there were 48 SNPs in 15 regions with P = 561027 to
1024. Five SNPs from four of these loci were genotyped in the
stage 3 samples (2,204 unaffected, 442 with ovarian cancer). Three
SNPs showed additional evidence of association with ovarian
cancer risk (P,0.02, Table 2; Table S5). In the combined stage 1–
3 analyses, SNPs rs17631303 and rs183211 (r2 = 0.68) on
chromosome 17q21.31 had P-values for association of 161028
and 361028 respectively, and rs4691139 at 4q32.3 had a P-value
of 3.461028 (Table 2).
The minor alleles of rs17631303 (HR = 1.27, 95%CI:1.17–1.38)
and rs183211 (HR = 1.25, 95%CI: 1.16–1.35) at 17q21.31 were
associated with increased ovarian cancer risk (Table 2). Analysis of
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the associations within a competing risks framework, revealed no
association with breast cancer risk (Table 3). The ovarian cancer
effect size was maintained in the competing risk analysis but the
significance of the association was slightly weaker (P = 261026–
161025). This is expected because 663 ovarian cancer cases
occurring after a primary breast cancer diagnosis were excluded
for this analysis. The evidence of association was somewhat
stronger under the genotype-specific model (2-df P = 1.661029
Table 2. Associations with breast and ovarian cancer risk for SNPs found to be associated with risk at all 3 stages of the
experiment.
SNP, Chr, Position, Allele1/
Allele2 Stage Number Allele 2 Frequency HR* (95% CI)
Unaffected Affected Unaffected Affected Per Allele Heterozygote Homozygote P-trend
Breast Cancer
rs2290854, 1q32, 202782648, G/A Stage 1 1104 1283 0.30 0.34 1.19 (1.08–1.30) 1.28 (1.12–1.47) 1.31 (1.06–1.61) 4.261024
Stage 2 4681 4637 0.31 0.33 1.09 (1.03–1.16) 1.10 (1.02–1.19) 1.18 (1.03–1.35) 0.003
Stages1+2 5785 5920 0.31 0.33 1.12 (1.06–1.17) 1.15 (1.07–1.23) 1.21 (1.08–1.36) 1.761025
Stage 3 1252 1393 0.30 0.33 1.19 (1.07–1.32) 1.24 (1.07–1.43) 1.36 (1.06–1.74) 0.0013
Combined 7037 7313 0.31 0.33 1.13 (1.08–1.18) 1.16 (1.09–1.24) 1.24 (1.11–1.37) 1.461027
rs6682208, 1q32, 202832806, G/A Stage 1 1104 1283 0.32 0.35 1.14 (1.04–1.25) 1.24 (1.09–1.42) 1.20 (0.98–1.47) 0.0070
Stage 2 4681 4637 0.32 0.34 1.10 (1.04–1.17) 1.09 (1.01–1.19) 1.21 (1.06–1.38) 0.0014
Stages1+2 5785 5920 0.32 0.34 1.11 (1.05–1.17) 1.13 (1.05–1.21) 1.21 (1.08–1.35) 5.461025
Stage 3 1250 1394 0.30 0.34 1.19 (1.07–1.32) 1.31 (1.14–1.51) 1.28 (1.01–1.63) 8.661024
Combined 7035 7314 0.32 0.34 1.12 (1.07–1.17) 1.16 (1.09–1.23) 1.22 (1.11–1.35) 4.361027
rs11196174, 10q25.3, 114724086,
A/G
Stage 1 1103 1282 0.27 0.32 1.15 (1.05–1.27) 1.17 (1.03–1.34) 1.31 (1.05–1.63) 0.0038
Stage 2 4681 4636 0.29 0.31 1.10 (1.04–1.17) 1.13 (1.04–1.23) 1.17 (1.01–1.35) 0.0017
Stages1+2 5784 5918 0.28 0.31 1.12 (1.06–1.18) 1.14 (1.06–1.23) 1.21 (1.07–1.37) 3.161025
Stage 3 1251 1393 0.28 0.31 1.16 (1.05–1.29) 1.08 (0.93–1.25) 1.46 (1.15–1.85) 0.0057
Combined 7035 7311 0.28 0.31 1.13 (1.07–1.18) 1.13 (1.06–1.21) 1.26 (1.13–1.40) 7.561027
rs11196175, 10q25.3, 114726604,
A/G
Stage 1 1101 1280 0.27 0.31 1.15 (1.05–1.27) 1.18 (1.03–1.35) 1.29 (1.03–1.62) 0.0043
Stage 2 4674 4627 0.28 0.30 1.10 (1.03–1.17) 1.13 (1.04–1.22) 1.17 (1.01–1.35) 0.0020
Stages1+2 5775 5907 0.28 0.30 1.12 (1.06–1.18) 1.14 (1.06–1.22) 1.21 (1.07–1.37) 3.961025
Stage 3 1251 1394 0.27 0.31 1.16 (1.04–1.29) 1.06 (0.91–1.22) 1.48 (1.17–1.87) 0.0075
Combined 7026 7301 0.28 0.31 1.12 (1.07–1.18) 1.12 (1.05–1.20) 1.26 (1.13–1.41) 1.261026
Ovarian Cancer
rs17631303, 17q21, 40872185, A/G Stage 1 1797 574 0.19 0.25 1.46 (1.22–1.74) 1.36 (1.01–1.68) 2.46 (1.53–3.96) 1.361025
Stage 2 7996 1257 0.19 0.21 1.20 (1.07–1.35) 1.10 (0.96–1.26) 1.83 (1.34–2.48) 1.561023
Stages1+2 9793 1831 0.19 0.22 1.27 (1.16–1.40) 1.15 (1.03–1.29) 2.03 (1.16–2.61) 3.061027
Stage 3 2204 442 0.17 0.21 1.27 (1.07–1.51) 1.24 (0.99–1.56) 1.67 (1.07–2.62) 0.014
Combined 11997 2273 0.19 0.22 1.27 (1.17–1.38) 1.17 (1.06–1.29) 1.95 (1.57–2.42) 1.461028
rs183211, 17q21, 42143493, G/A Stage 1 1812 575 0.22 0.28 1.45 (1.23–1.71) 1.37 (1.11–1.69) 2.29 (1.53–3.41) 2.561025
Stage 2 8054 1264 0.23 0.25 1.20 (1.07–1.33) 1.13 (0.99–1.28) 1.62 (1.22–2.14) 1.161023
Stages1+2 9866 1839 0.23 0.26 1.25 (1.15–1.37) 1.16 (1.04–1.29) 1.83 (1.46–2.28) 5.761027
Stage 3 2204 442 0.22 0.26 1.25 (1.06–1.48) 1.15 (0.92–1.44) 1.79 (1.21–2.67) 0.018
Combined 12070 2281 0.23 0.26 1.25 (1.16–1.35) 1.16 (1.05–1.27) 1.82 (1.5–2.21) 3.161028
rs4691139, 4q32.3, 166128171, A/G Stage 1 1812 575 0.47 0.53 1.24 (1.08–1.42) 1.46 (1.13–1.88) 1.55 (1.16–2.05) 3.661023
Stage 2 8054 1264 0.48 0.52 1.18 (1.08–1.29) 1.29 (1.10–1.50) 1.40 (1.17–1.67) 1.361024
Stages1+2 9866 1839 0.48 0.52 1.20 (1.11–1.29) 1.33 (1.17–1.52) 1.44 (1.24–1.67) 1.161026
Stage 3 2204 441 0.47 0.52 1.20 (1.04–1.39) 1.19 (0.91–1.54) 1.44 (1.08–1.94) 961023
Combined 12070 2280 0.48 0.52 1.20 (1.17–1.38) 1.30 (1.16–1.46) 1.44 (1.26–1.65) 3.461028
*HRs estimated under the single disease risk models.
doi:10.1371/journal.pgen.1003212.t002
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and P = 2.661029 for rs17631303 and rs183211 respectively in all
samples combined) with larger HR estimates for the rare
homozygote genotypes than those expected under a multiplicative
model (Table 2).
Previous studies of the known common ovarian cancer
susceptibility alleles found significant associations with ovarian
cancer for both BRCA1 and BRCA2 carriers [6,7]. Thus, we
evaluated the associations between the 17q21.31 SNPs and
ovarian cancer risk for BRCA2 carriers using iCOGS genotype
data (7580 unaffected and 631 affected). Both rs17631303 and
rs183211 were associated with ovarian cancer risk for BRCA2
carriers (P = 1.9861024 and 9.2661024), with similar magnitude
and direction of association as for BRCA1 carriers. Combined
analysis of BRCA1 and BRCA2 mutation carriers provided strong
evidence of association (P = 2.80610210 and 2.0161029, Table 4).
The combined analysis of stage 1 and 2 samples, and BRCA2
carriers, identified seven SNPs on the iCOGS array (pairwise r2
range: 0.68–1.00) from a 1.3 Mb (40.8–42.1 Mb, build 36.3) region
of 17q21.31 that were strongly associated (P,1.2761029) with
ovarian cancer risk (Table 4, Figure 2). Stepwise-regression analysis
based on observed genotype data retained only one of the seven
SNPs in the model, but it was not possible to distinguish between the
SNPs. Imputation through the 1000 Genomes Project, revealed
several SNPs in 17q21.31 with stronger associations (Figure 2, Table
S8) than the most significant genotyped SNP in the combined
BRCA1/2 analysis (rs169201, P = 6.24610211). The most signifi-
cant SNP (rs140338099 (17-44034340), P = 3610212), located in
MAPT, was highly correlated (r2 = 0.78) with rs169201 in NSF
(Figure 2). This locus appears to be distinct from a previously
identified ovarian cancer susceptibility locus located .1 Mb distal
on 17q21 (spanning 43.3–44.3 Mb, build 36.3) [30]. None of the
SNPs in the novel region were strongly correlated with any of the
SNPs in the 43.3–44.3 Mb region (maximum r2 = 0.07, Figure S8).
The most significantly associated SNP from the BRCA1 GWAS
from the 43.3–44.3 Mb locus was rs11651753 (p = 4.661024)
(Table 1) (r2,0.023 with the seven most significant SNPs in the
novel 17q21.31 region). An analysis of the joint associations of
rs11651753 and rs17631303 from the two 17q21 loci with ovarian
cancer risk for BRCA1 carriers (Stage 1 and 2 samples) revealed that
both SNPs remained significant in the model (P-for inclu-
sion = 0.001 for rs11651753, 1.261026 for rs17631303), further
suggesting that the two regions are independently associated with
ovarian cancer for BRCA1 carriers.
The minor allele of rs4691139 at the novel 4q32.3 region was
also associated with an increased ovarian cancer risk for BRCA1
carriers (per-allele HR = 1.20, 95%CI:1.17–1.38, Table 2), but
was not associated with breast cancer risk (Table 3). No other
SNPs from the 4q32.3 region on the iCOGS array were more
significantly associated with ovarian cancer for BRCA1 carriers.
Analysis of associations with variants identified through 1000
Genomes Project-based imputation of the Stage 1 and 2 samples,
revealed 19 SNPs with stronger evidence of association
(P = 5.461027 to 1.161026) than rs4691139 (Figure S9). All were
highly correlated (pairwise r2.0.89) and the most significant
(rs4588418) had r2 = 0.97 with rs4691139. There was no evidence
for association between rs4691139 and ovarian cancer risk for
BRCA2 carriers (HR = 1.08, 95%CI: 0.96–1.21, P = 0.22).
Absolute risks of developing breast and ovarian cancer
The current analyses suggest that 10 loci are now known to be
associated with breast cancer risk for BRCA1 mutation carriers:
1q32, 10q25.3, 19p13, 6q25.1, 12p11, TOX3, 2q35, LSP1 and
RAD51L1 all reported here and TERT [31]. Similarly, seven loci
are associated with ovarian cancer risk for BRCA1 mutation
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carriers: 9p22, 8q24, 3q25, 17q21, 19p13, 17q21.31 and 4q32.3.
Figure S10 shows the range of combined HRs at different
percentiles of the combined genotype distribution, based on the
single SNP HR and minor allele estimates from Table 1, Table 2,
and Table S4 and for TERT from Bojesen et al [31] and assuming
that all SNPs interact multiplicatively. Relative to BRCA1
mutation carriers at lowest risk, the median, 5th and 95th
percentile breast cancer HRs were 3.40, 2.27, and 5.35
respectively. These translate to absolute risks of developing breast
cancer by age 80 of 65%, 51% and 81% for those at median, 5th
and 95th percentiles of the combined genotype distribution
(Figure 3, Figure S10). Similarly, the median, 5th and 95th
percentile combined HRs for ovarian cancer were 6.53, 3.75 and
11.12 respectively, relative to those at lowest ovarian cancer risk
(Figure S10). These HRs translate to absolute risks of developing
ovarian cancer of 44%, 28% and 63% by age 80 for the median,
5th and 95th percentile of the combined genotype distribution
(Figure 3).
Discussion
In this study we analyzed data from 11,705 BRCA1 mutation
carriers from CIMBA who were genotyped using the iCOGS
high-density custom array, which included 31,812 SNPs selected
on the basis of a BRCA1 GWAS. This study forms the large-scale
replication stage of the first GWAS of breast and ovarian cancer
risk modifiers for BRCA1 mutation carriers. We have identified a
novel locus at 1q32, containing the MDM4 oncogene, that is
associated with breast cancer risk for BRCA1 mutation carriers
(P,561028). A separate locus at 10q23.5, containing the TCF7L2
gene, provided strong evidence of association with breast cancer
risk for BRCA1 carriers but did not reach a GWAS level of
significance. We have also identified two novel loci associated with
ovarian cancer for BRCA1 mutation carriers at 17q21.31 and
4q32.2 (P,561028). We further confirmed associations with loci
previously shown to be associated with breast or ovarian cancer
risk for BRCA1 mutation carriers. In most cases stronger
associations were detected with either the same SNP reported
previously (due to increased sample size) or other SNPs in the
regions. Future fine mapping studies of these loci will aim to
identify potentially causal variants for the observed associations.
Although the 10q25.3 locus did not reach the strict GWAS level
of significance for association with breast cancer risk, the
association was observed at all three independent stages of the
experiment. Additional evidence for the involvement of this locus
in breast cancer susceptibility comes from parallel studies of the
Breast Cancer Association Consortium (BCAC). SNPs at 10q25.3
had also been independently selected for inclusion on the iCOGS
array through population based GWAS of breast cancer. Analyses
of those SNPs in BCAC iCOGS studies also found that SNPs at
10q25.3 were associated with breast cancer risk in the general
population [32]. Thus, 10q25.3 is likely a breast cancer risk-
modifying locus for BRCA1 mutation carriers. The most significant
SNPs at 10q25.3 were located in TCF7L2, a transcription factor
that plays a key role in the Wnt signaling pathway and in glucose
homeostasis, and is expressed in normal and malignant breast
tissue (The Cancer Genome Atlas (TCGA)). Variation in the
TCF7L2 locus has previously been associated with Type 2 diabetes
in a number of GWAS. The most significantly associated SNPs
with Type 2 diabetes (rs7903146 and rs4506565) [22,33] were also
associated with breast cancer risk for BRCA1 mutation carriers in
stage 1 and 2 analyses (p = 3.761024 and p = 2.561024 respec-
tively); these SNPs were correlated with the most significant hit
(rs11196174) for BRCA1 breast cancer (r2 = 0.40 and 0.37 based
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Figure 2. Mapping of the 17q21 locus. Top 3 panels: P-values of association (2log10 scale) with ovarian cancer risk for genotyped and imputed
SNPs (1000 Genomes Project CEU), by chromosome position (b.37) at the 17q21 region, for BRCA1, BRCA2 mutation carriers and combined. Results
based on the kinship-adjusted score test statistic (1 d.f.). Fourth panel: Genes in the region spanning (43.4–44.9 Mb, b.37) and the location of the most
significant genotyped SNPs (in red font) and imputed SNPs (in black font). Bottom panel: Pairwise r2 values for genotyped SNPs on iCOG array in the
17q21 region covering positions (43.4–44.9 Mb, b.37).
doi:10.1371/journal.pgen.1003212.g002
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on stage 1 and 2 samples). This raises the possibility that variants
in this locus influence breast cancer indirectly through effects on
cellular metabolism.
We found that SNPs at 1q32 were primarily associated with
ER-negative breast cancer risk for BRCA1 mutation carriers.
There was also evidence of association with ER-negative breast
cancer for BRCA2 mutation carriers. SNPs at the 1q32 region were
independently selected for inclusion on iCOGS through GWAS of
breast cancer in the general population by BCAC. In parallel
analyses of iCOGS data by BCAC, 1q32 was found to be
associated with ER-negative breast cancer [34] but not overall
breast cancer risk [32]. Taken together, these results are in
agreement with our findings and in line with the observation that
the majority of BRCA1 breast cancers are ER-negative. However,
they are not in agreement with a previous smaller candidate-gene
study that found an association between a correlated SNP in
MDM4 (r2.0.85) and overall breast cancer risk [35]. The 1q32
locus includes the MDM4 oncogene which plays a role in
regulation of p53 and MDM2 and the apoptotic response to cell
stress. MDM4 is expressed in breast tissue and is amplified and
overexpressed along with LRRN2 and PIK3C2B in breast and other
tumor types (TCGA) [36–38]. Although fine mapping will be
necessary to identify the functionally relevant SNPs in this locus,
we found evidence of cis-regulatory variation impacting MDM4
expression [39–41] (Text S1, Table S9, Figure S11), suggesting
that common variation in the 1q32 locus may influence the risk of
breast cancer through direct effects on MDM4 expression.
Several correlated SNPs at 17q21.31 from the iCOGS array
provided strong evidence of association with ovarian cancer risk in
both BRCA1 and BRCA2 mutation carriers. A subsequent analysis
of these SNPs, which were selected through the BRCA1 GWAS, in
case-control samples from the Ovarian Cancer Association
Consortium (OCAC), revealed that the 17q21.31 locus is
associated with ovarian cancer risk in the general population
[Wey et al, personal communication]. Thus, 17q21.31 is likely a
novel susceptibility locus for ovarian cancer in BRCA1 mutation
carriers. The most significant associations at 17q21.31 were
clustered in a large region of strong linkage disequilibrium which
has previously been identified as a ‘‘17q21.31 inversion’’ (,900 kb
long) consisting of two haplotypes (termed H1 and H2) [42]. The
minor allele of rs2532348 (MAF = 0.21), which tags H2, was
associated with increased ovarian cancer risk for BRCA1 mutation
carriers (Table 4). The 1.3 Mb 17q21.31 locus contains 13 genes
and several predicted pseudogenes (Figure 2), several of which are
Figure 3. Predicted breast and ovarian cancer absolute risks for BRCA1 mutation carriers at the 5th, 10th, 90th, and 95th percentiles
of the combined SNP profile distributions. The minimum, maximum and average risks are also shown. Predicted cancer risks are based on the
associations of known breast or ovarian cancer susceptibility loci (identified through GWAS) with cancer risk for BRCA1 mutation carriers and loci
identified through the present study. Breast cancer risks based on the associations with: 1q32, 10q25.3, 19p13, 6q25.1, 12p11, TOX3, 2q35, LSP1,
RAD51L1 (based on HR and minor allele frequency estimates from Table 1, Table 2, and Table S4) and TERT [31]. Ovarian cancer risks based on the
associations with: 9p22, 8q24, 3q25, 17q21, 19p13 (Table 1) and 17q21.31, 4q32.3 (Table 2). Only the top SNP from each region was chosen. Average
breast and ovarian cancer risks were obtained from published data [25]. The methods for calculating the predicted risks have been described
previously [28].
doi:10.1371/journal.pgen.1003212.g003
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expressed in normal ovarian surface epithelium and ovarian
adenocarcinoma [43]. Variation in this region has been associated
with Parkinson’s disease (MAPT, PLEKHM1, NSF, c17orf69)
progressive supranuclear palsy (MAPT), celiac disease (WNT3),
bone mineral density (CRHR1) (NHGRI GWAS catalog) and
intracranial volume [44]. Of the top hits for these phenotypes,
SNP rs199533 in NSF, previously associated with Parkinson’s
disease [45] and rs9915547 associated with intracranial volume
[44] were strongly associated with ovarian cancer (P,1029 in
BRCA1/2 combined). Whether these phenotypes have shared
causal variants in this locus remains to be elucidated. Further
exploration of the functional relevance of the strongest hits in the
17q21.31 locus (P,1028 in BRCA1/2 combined) provided
evidence that cis-regulatory variation alters expression of several
genes at 17q21, including PLEKHM1, c17orf69, ARHGAP27,
MAPT, KANSL1 and WNT3 [39,41] (Table S9, Figure S12),
suggesting that ovarian cancer risk may be associated with altered
expression of one or more genes in this region.
Our analyses revealed that a second novel locus at 4q32.3 was
also associated with ovarian cancer risk for BRCA1 mutation
carries (P,561028). However, we found no evidence of associ-
ation for these SNPs with ovarian cancer risk for BRCA2 mutation
carriers using 8,211 CIMBA samples genotyped using the iCOGS
array. Likewise, no evidence of association was found between
rs4691139 at 4q32.3 and ovarian cancer risk in the general
population based on data by OCAC data derived from 18,174
cases and 26,134 controls (odds ratio = 1.00, 95%CI:0.97–1.04,
P = 0.76) [46]. The confidence intervals rule out a comparable
effect to that found in BRCA1 carriers. Therefore, our findings
may represent a BRCA1-specific association with ovarian cancer
risk, the first of its kind. The 4q32.2 region contains several
members of the TRIM (Tripartite motif containing) gene family,
c4orf39 and TMEM192. TRIM60, c4orf39 and TMEM192 are
expressed in normal ovarian epithelium and/or ovarian tumors
(TCGA).
In summary, we have identified a novel locus at 1q32 associated
with breast cancer risk for BRCA1 mutation carriers, which was
also associated with ER-negative breast cancer for BRCA2 carriers
and in the general population. A separate locus at 10q23.5
provided strong evidence of association with breast cancer risk for
BRCA1 carriers. We have also identified 2 novel loci associated
with ovarian cancer for BRCA1 mutation carriers. Of these, the
4q32.2 locus was associated with ovarian cancer risk for BRCA1
carriers but not for BRCA2 carriers or in the general population.
Additional functional characterisation of the loci will further
improve our understanding of the biology of breast and ovarian
cancer development in BRCA1 carriers. Taken together with other
identified genetic modifiers, 10 loci are now known to be
associated with breast cancer risk for BRCA1 mutation carriers
(1q32, 10q25.3, 19p13, 6q25.1, 12p11, TOX3, 2q35, LSP1,
RAD51L1 and TERT and seven loci are known to be associated
with ovarian cancer risk for BRCA1 mutation carriers (9p22, 8q24,
3q25, 17q21, 19p13 and 17q21.31, 4q32.3).
As BRCA1 mutations confer high breast and ovarian cancer
risks, the results from the present study, taken together with other
identified genetic modifiers, demonstrate for the first time that they
can result in large differences in the absolute risk of developing
breast or ovarian cancer for BRCA1 between genotypes. For
example, the breast cancer lifetime risks for the 5% of BRCA1
carriers at lowest risk are predicted to be 28–50% compared to
81–100% for the 5% at highest risk (Figure 3). Based on the
distribution of ovarian cancer risk modifiers, the 5% of BRCA1
mutation carriers at lowest risk will have a lifetime risk of
developing ovarian cancer of 28% or lower whereas the 5% at
highest risk will have a lifetime risk of 63% or higher. Similarly,
the breast cancer risk by age 40 is predicted to be 4–9% for the 5%
of BRCA1 carriers at lowest risk compared to 20–49% for the 5%
at highest risk, whereas the ovarian cancer risk at age 50 ranges
from 3–7% for the 5% at lowest risk and from 18–47% for the 5%
at highest risk. The risks at all ages for the 10% at highest or lowest
risk of breast and ovarian cancer are predicted to be similar to
those for the highest and lowest 5%. Thus, at least 20% of BRCA1
mutation carriers are predicted to have absolute risks of disease
that are different from the average BRCA1 carriers. These large
differences in cancer risks may have practical implications for the
clinical management of BRCA1 mutation carriers, for example in
deciding the timing of interventions. Such risks, in combination
with other lifestyle and hormonal risk factors could be incorpo-
rated into cancer risk prediction algorithms for use by clinical
genetics centers. These algorithms could then be used to inform
the development of effective and consistent clinical recommenda-
tions for the clinical management of BRCA1 mutation carriers.
Supporting Information
Figure S1 Multidimensional scaling of stage 1 and stage 2
(genotyped on iCOGS) samples. Panel A: Graphical representa-
tion of the first two components, for the BRCA1 carriers, for
subgroups defined by the common 185delAG (c.68_69delAG)
BRCA1 Jewish founder mutation, the 5382insC (c.5266dupC)
Eastern European founder mutation and Hapap individuals
(CEU: European; ASI: Includes CHB and JPT populations;
YRI: African). Panel B: Red dots represent the samples with
.22% non-European ancestry, excluded from the analysis.
(PDF)
Figure S2 Genotyping cluster plots in the BRCA1 samples for
the key associated SNPs.
(PDF)
Figure S3 Quantile-quantile plot for the kinship adjusted score
test statistic for stage 2 samples (1 degree of freedom x2 trend test)
for the associations with breast cancer (panel A) and ovarian
cancer (panel B) risk for BRCA1 mutation carriers. The y = x line
corresponds to the expected distribution, under the hypothesis of
no inflation. Inflation was estimated using the values of the lowest
90% test statistics.
(PDF)
Figure S4 P-values (on 2log10 scale) by chromosomal position,
for the associations of 31,812 BRCA1 GWAS SNPs with breast
(panel A) and ovarian (panel B) cancer risk for BRCA1 mutation
carriers in the combined stage 1 and stage 2 samples. Blue lines
correspond to a P-value of 1025; red lines correspond to P-value
561028.
(PDF)
Figure S5 Forest plots of the associations by country of residence
of BRCA1 mutation carriers in the combined stage 1, stage 2 and
stage 3 samples for SNPs found to be associated with breast and
ovarian cancer risk for BRCA1 mutation carriers. Squares indicate
the country specific, per-allele HR estimates for the SNPs. The
area of the square is proportional to the inverse of the variance of
the estimate. Horizontal lines indicate 95% confidence intervals.
There was some evidence of heterogeneity in country-specific HR
estimates for the rs2290854 and rs6682208 SNP (P = 0.04 and
0.02 respectively, Figure S3), but after accounting for opposite
effects of these SNPs in Finland/Denmark, there was no evidence
of heterogeneity. There was some evidence of heterogeneity in the
country-specific HRs for rs17631303 (P-het = 0.004, df = 19) but
this was no longer present after excluding one country (Poland, P-
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heterogeneity for correlated SNP rs183211 (P-het = 0.10). There
was no evidence of hereterogeneity in the country-specific HRs for
any of the other SNPs (P.0.68).
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Figure S6 MDM4 regional association plot using BRCA1 stage 1
and stage 2 samples. P-values for association (2log10 scale) with
breast cancer risk for BRCA1 mutation carriers for genotyped
SNPs (diamond symbols e) and SNPs imputed from the 1000
genomes project data (square symbols %), by position (hg18) on
chromosome 1. Red gradient represents r2 value with the most
significant genotyped SNP rs4951407. The blue peaks represent
recombination rate in the region.
(PDF)
Figure S7 TCF7L2 regional association plot using BRCA1 stage
1 and stage 2 samples. P-values for association (2log10 scale) with
breast cancer risk for BRCA1 mutation carriers for genotyped
SNPs (diamond symbols e) and SNPs imputed from the 1000
genomes project data (square symbols %), by position (hg18) on
chromosome 1. Missing genotypes were replaced by imputed
results. Red gradient represents r2 value with the most significant
genotyped SNP rs11196174. The blue peaks represent recombi-
nation rate in the region.
(PDF)
Figure S8 Linkage disequilibrium patterns between the SNPs in
the novel (17q21.31) and previously identified regions on 17q21.
SNPs in the novel region are uncorrelated with SNPs in the 43.3–
44.3 Mb region (positions according to hg build 36.3).
(PDF)
Figure S9 4q32.3 regional association plot using BRCA1 stage 1
and stage 2 samples. P-values for association (2log10 scale) with
ovarian cancer risk for BRCA1 mutation carriers for genotyped
SNPs (diamond symbols e) and imputed SNPs from the 1000
genomes project data (square symbols %), by position (hg18) on
chromosome 1. Red gradient represents r2 value with the most
significant genotyped SNP rs4691139. Blue peaks represent
recombination rate in the region.
(PDF)
Figure S10 Combined Hazard Ratios (HR) for breast and
ovarian cancer for BRCA1 mutation carriers. (A) HR for Breast
Cancer based on 10 loci associated with breast cancer risk for
BRCA1 mutation carriers. (B) Ovarian Cancer based on 7 loci
associated with ovarian cancer risk for BRCA1 mutation carriers.
All HRs computed relative to the lowest risk category. The Y-axes
translate the combined HRs into absolute risks of developing
breast or ovarian cancer by age 80. The absolute risks and HRs at
different percentiles of the combined genotype distribution are also
marked. The combined HRs were obtained under the assumption
that the loci interact multiplicatively.
(PDF)
Figure S11 Cis-eQTL and allelic expression (AE) analyses at
MDM4 locus. A) Cis-eQTLs for SNPs at MDM4 locus using
expression data from primary human osteoblasts (HOb). B) AE
mapping for cis-regulatory variation in MDM4 locus using primary
skin fibroblasts. Coordinates (hg18) for locus shown on top; blue
tracks indicate the 2log10(P value) of the association across all
SNPs tested. The location of transcripts in this region is shown
below.
(PDF)
Figure S12 Cis-eQTL and allelic expression (AE) analyses at
chr17q21.31 locus. (Upper panel) Cis-eQTLs for SNPs at
c17orf69 locus using expression data from primary human
osteoblasts. Allelic expression mapping for cis-regulatory variation
in KANSL1 (middle panel) and WNT3 loci (lower panel) using a
CEU population panel of lymphoblastoid cells. Coordinates (hg18)
for loci are shown on top; blue tracks indicate the 2log10(P value)
of the association across all SNPs tested. The location of transcripts
in these regions are shown.
(PDF)
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